Navigation Links
Unigene's Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
Date:12/12/2012

BOONTON, N.J., Dec. 12, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society. The article will be published in the paper version of the journal in the coming months.

This peer reviewed manuscript, entitled, "Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant Human Parathyroid Hormone [rhPTH(1-31)NH2] in Postmenopausal Women with Osteoporosis," provides the full efficacy and safety data from Unigene's Phase 2 clinical study of oral PTH in the treatment of osteoporosis in 97 postmenopausal women.  Kim Henriksen, MSc, PhD, Head of Musculoskeletal Diseases at Nordic Bioscience served as the lead author of the article, which was jointly prepared by authors from Nordic Bioscience, Unigene Laboratories, the Center for Clinical and Basic Research (CCBR) and GlaxoSmithKline (GSK).

Ashleigh Palmer, Unigene's Chief Executive Officer, stated, "We are extremely pleased that a peer-reviewed article detailing the positive Phase 2 results from our oral PTH program was published in such a prestigious scientific journal as Bone.  The data and analysis once again demonstrate the strength of Unigene's proprietary oral peptide drug delivery technology and the clinical potential and commercial viability of our oral PTH analog.  I would like to extend my congratulations to Dr. Henriksen for leading the publication effort and to the entire team of contributors from Nordic Bioscience, CCBR, GSK and Unigene for their tremendous wor
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
3. uniQure Initiates Phase I in Acute Intermittent Porphyria
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Phase II Trial of Sanofi JAK2 Inhibitor in Myelofibrosis Met Primary Endpoint
8. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... Ad, " This is Medicare and America at ... WASHINGTON, Dec. 9 The SCOOTER Store today launched a ... and cost savings associated with Medicare,s Power Mobility Benefit, which ... to receive power wheelchairs. , With budget cuts likely in ...
... , ROCKVILLE, Md., Dec. 9 Novavax, Inc. (Nasdaq: ... closed its previously announced public offering of 6,800,000 shares of ... net proceeds from the sale of the shares, after underwriting ... which will be used for preclinical studies and clinical trials ...
Cached Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2
(Date:9/22/2014)... people both exercise more and drink more , Study ... activity , Findings differ from past research on physical ... Medicine study finds that on days when people exercise ... more alcohol, too. , This is the only study ... for self-reporting physical activity and alcohol use. , "Monday ...
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... Boston Scientific Corp. continue to move forward in ... District Court, Southern District of West Virginia, Bernstein ... new Docket Control Order was issued by the ... of matters pertaining to the upcoming trial for ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... September 22, 2014 An inventor and ... to the problem of side-sleeping. "My lower arm always ... I designed a solution to this problem," she said. ... than to have your arm 'fall asleep.'" , The ... or her side more comfortably. It avoids pain and ...
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
Breaking Medicine News(10 mins):Health News:We drink more alcohol on gym days 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4
... 7 NHS Choices ( http://www.nhs.uk ), the,online ... updated online information,resource, Health A-Z, aimed to help ... treatments., Based on NHS accredited information, the ... need,to know on a topic in seconds, providing ...
... conventional gasoline and stored electricity can be no ... technology is developed, according to researchers in France. ... Automotive Technology and Management, they suggest that the ... more sustainable fuel-cell powered electric vehicles. , Jean-Jacques ...
... Pa., Feb. 7 The following release was issued,today ... Milberg Weiss,LLP:, UNITED STATES DISTRICT COURT ... MARTEK BIOSCIENCES CORP. (Ticker: MATK) SECURITIES LITIGATION Civil ... SETTLEMENT AND SETTLEMENT HEARING TO: ALL PERSONS AND ...
... Learning, NEW YORK, Feb. 7 Immediate ... quality medical care and can mean the,difference between ... Health,Record (EHR) systems, used by physicians, offices in ... those critical moments.,McGraw-Hill Higher Education has published a ...
... on Bisphenol,A in Baby Bottles, Food and Beverage Containers, ... state,and national environmental health organizations in the U.S. and ... of bisphenol A (BPA) in baby,bottles and other food ... study that demonstrates the toxic chemical BPA leaches from ...
... WEST CHESTER, Ohio, Feb. 7 AtriCure, Inc.,(Nasdaq: ... in cardiac surgical,ablation products, announced today the appointment of ... Collar recently retired from a,distinguished career with The Procter ... Global Pharmaceuticals and Personal Health,business., "We are pleased ...
Cached Medicine News:Health News:The trouble with hybrids 2Health News:Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation 2Health News:McGraw-Hill Higher Education Publishes Text on Innovative Electronic Health Records System 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 2Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 3Health News:Baby Bottles Leach Toxic Chemical, According to New U.S. and Canadian Study 4Health News:AtriCure Appoints Mark A. Collar to its Board of Directors 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: